Mersana Therapeutics — Investor Day (January 2021)
53 slides from Mersana Therapeutics's investor day presentation, Jan 5, 2021

Slide 1: Accelerating ADC Innovation: Virtual Analyst & Investor Day
Accelerating ADC Innovation …because patients are waiting Virtual Analyst & Investor Day January 5, 2021

Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains “forward - looking” statements within the meaning of federal securities laws . These forward - looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available to managem

Slide 3: Today's Agenda
Today’s Agenda 3 Topic Speaker Opening Remarks Anna Protopapas, President & CEO XMT - 1536 Pivotal Registration Strategy in Ovarian Cancer Arvin Yang, MD, PhD, Chief Medical Officer XMT - 1536 Phase 1 Ovarian Cancer Expansion Study Data Update Debra L. Richardson, MD, Associate Professor and Section

Slide 4: 2020 Was a Transformative Year for Mersana
2020 Was a Transformative Year for Mersana 4 Corporate XMT - 1592 (NaPi2b Dolasynthen) XMT - 2056 (1 st Immunosynthen ADC) XMT - 1660 (B7 - H4 DolaLock ADC) XMT - 1536 (NaPi2b Dolaflexin) Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Strengthened Balance Sheet Added Experienced CMO Added Experienced SVP R

Slide 5: Poised for Significant Value Inflection Points and Continued Momentum in 2021
Poised for Significant Value Inflection Points and Continued Momentum in 2021 5 1 XMT - 1536 in Ovarian IND Submission Q1 2022 5 XMT - 2056 (Immunosynthen) IND Submission Q1 2022 Select Lead in NSCLC Initiate Single - Arm Registration Strategy Initiate Lifecycle Management Studies / Combinations IND

Slide 6: XMT-1536 Has a New Name: upifitamab rilsodotin or UpRi
XMT - 1536 Has a New Name 6 upifitamab rilsodotin or UpRi, for short

Slide 7: UpRi (XMT-1536): An Opportunity to Deliver a Potentially Foundational Therapy for Ovarian Cancer
7 Earlier Lines of Therapy Single - Arm Registration Strategy in Platinum Resistant Disease New Combinations UpRi (XMT - 1536): An Opportunity to Deliver a Potentially Foundational Therapy for Ovarian Cancer • In a heavily - pretreated ovarian cancer population: – Proof of concept, >30% ORR in ovari

Slide 8: UpRi (XMT-1536): First-in-Class Dolaflexin ADC Targeting NaPi2b
UpRi (XMT - 1536): First - in - Class Dolaflexin ADC Targeting NaPi2b Single - Arm Registration Strategy in Ovarian Cancer Arvin Yang, MD, PhD Chief Medical Officer

Slide 9: Strategy Informed by End of Phase Meeting and Meeting Minutes
Strategy Informed by End of Phase Meeting and Meeting Minutes UPLIFT Strategy: Key Areas Discussed with FDA • Population with high unmet medical need • Performance of current standard of care • Design of single - arm registration cohort • Primary and secondary endpoints • Biomarker validation strate

Slide 10: Appropriate Benchmarks for Current Standard of Care in Platinum-Resistant Ovarian Cancer
Appropriate Benchmarks for Current Standard of Care in Platinum - Resistant Ovarian Cancer Study Demographics Control Arm Control Arm Performance Forward I ESMO 2019 1 – 3 Prior Median 2 Prior Prior PARPi: 10% Prior Bev: 47% PLD, Topotecan, Weekly Paclitaxel ORR 12% Javelin 200 SGO 2019 1 – 3 Prior

Slide 11: UPLIFT: Single-Arm Registration Strategy in Platinum Resistant Ovarian Cancer
UPLIFT: Single - Arm Registration Strategy in Platinum Resistant Ovarian Cancer 11 Primary Endpoint: Confirmed ORR in higher NaPi2b Key Secondary Endpoint: Confirmed ORR in overall population Other Secondary Endpoints: • Duration of Response • Safety Inclusion Criteria: Platinum Resistant Ovarian Ca

Slide 12: Significant Time Advantage in Amending with the Single-Arm UPLIFT Cohort
Significant Time Advantage in Amending with the Single - Arm UPLIFT Cohort 12 Dose Escalation Cohort (Enrollment Complete in March 2020) Ovarian Cancer Expansion Cohort (Enrollment August 2019 – Q1 2021) UPLIFT: Single - Arm Registration Strategy in Platinum Resistant Ovarian Cancer (Planning Patien

Slide 13: Strategy to Deliver a Robust and Reproducible Commercial Diagnostic Assay
Strategy to Deliver a Robust and Reproducible Commercial Diagnostic Assay 13 • NaPi2b expression assessed with clinical assay in >80 patients • “Train” proposed commercial assay – Repeat assessment on all samples – Ensures same read regardless of lab and pathologist • Determine cutoff for UPLIFT Piv

Slide 14: UPLIFT Registration Strategy Creates Potential for Speed and Label Differentiation
UPLIFT Registration Strategy Creates Potential for Speed and Label Differentiation 14 • Streamlined Execution – Leverages expansion cohort enrollment momentum in high unmet need population for single - arm registration path • Broad Target Population – Includes patients with 4 prior lines of therapy,

Slide 15: UpRi Phase 1 Ovarian Cancer Expansion Cohort Data Update
UpRi (XMT - 1536): First - in - Class Dolaflexin ADC Targeting NaPi2b Phase 1 Ovarian Cancer Expansion Cohort Data Update Debra L. Richardson, MD Associate Professor and Section Chief, Division of Gynecological Oncology at OU Health Stephenson Cancer Center and the Sarah Cannon Research Institute Th

Slide 16: We thank the patients, their families and caregivers
We thank the patients, their families and caregivers for their contribution to this study UNTED STATES Allegheny Health Network, Pittsburgh, PA Arizona Oncology Associates, Tucson, AZ Billings Clinic, Billings, MT Dana Farber Cancer Institute, Boston, MA Emory University, Atlanta, GA Fox

Slide 17: Design for the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study
Design for the Ovarian Cancer Cohort of the XMT - 1536 (UpRi) Phase 1 Expansion Study 17 Ovarian Cancer Cohort • 1 - 3 prior lines in platinum resistant • 4 prior lines regardless of platinum status • High grade serous histology • Archived tumor and fresh biopsy (if medically feasible) for NaPi2b •

Slide 18: Patient Demographics and Disease Characteristics
Data cut off: 03 December 2020 Patient Demographics and Disease Characteristics 18 Ovarian Cancer Expansion Patients (N = 72) Age; years Median (range) 68 (33, 87) ECOG Performance Status; n (%) 0 1 26 (36) 46 (64) Primary Tumor Type a ; n (%) Ovarian Fallopian Tube Primary Peritoneal 55 (76) 11 (15

Slide 19: TRAEs Reported in ≥20% of Patients with Ovarian Cancer
TRAEs Reported in ≥20% of Patients with Ovarian Cancer (N = 72) a b d c XMT - 1536 (UpRi) Continues to Have a Consistent Tolerability Profile 19 a Fatigue includes preferred terms of asthenia and fatigue; b AST increase is transient in nature, recovers to baseline or to Grade 1 prior to the next dos

Slide 20: Safety Summary of XMT-1536 (UpRi) in Patients with Ovarian Cancer
Safety Summary of XMT - 1536 (UpRi) in Patients with Ovarian Cancer (N = 72) 20 Dose Modifications Patients, n (%) Any dose reduction, delay, or discontinuation due to TRAE 22 (31%) Dose reductions due to TRAE 17 (24%) Dose delays due to TRAE 8 (11%) Discontinuations due to TRAE 5 (7%) * Includes bo

Slide 21: Pneumonitis Case History and Program Level Review and Modifications
• Safety Review Committee identified a low frequency of pneumonitis cases which were generally low grade and resolved with dose delays, reductions, and/or treatment with steroids – 8 additional cases out of 145 treated patients – Grade 1/2 n=7, Grade 3 n=1 • Modifications to protocol – Enhanced guid

Slide 22: Continued Robust Activity Observed in Heavily-Pretreated Ovarian Cancer
Continued Robust Activity Observed in Heavily - Pretreated Ovarian Cancer 22 Best Response in Evaluable Patients with Ovarian Cancer (n = 47) All (n = 47) Higher NaPi2b O (n = 31) Lower NaPi2b OO (n = 13) NaPi2b Not Yet Determined (n = 3) CR; n(%) 2 (4) 2 (6) 0 0 PR; n(%) 11 (23) 8 (26) 2 (15) 1 (33

Slide 23: Deep Responses Observed in Heavily-Pretreated Ovarian Cancer
Deep Responses Observed in Heavily - Pretreated Ovarian Cancer 23 ** ** *** Maximum % Change from Baseline in Target Lesions in Patients with Ovarian Cancer (n = 45*) * 2 patients not included in waterfall plot as tumor measurement data missing in the database as of data cut; both patients h ad BOR

Slide 24: Responses Occur Early and Appear to Deepen Over Time
Responses with XMT - 1536 (UpRi) Occur Early and Appear to Deepen Over Time 24 Change from Baseline in Target Lesions in Patients with Ovarian Cancer (n = 45) H = Higher NaPi2b Expression; L = Lower NaPi2b Expression; ND = NaPi2b Expression not yet determined or tissue not available Tumor response o

Slide 25: Clear Trend to Longer Time on Study with Higher NaPi2b Expression
Clear Trend to Longer Time on Study with Higher NaPi2b Expression 25 Higher Lower ND Time on XMT - 1536 Study in Patients with Ovarian Cancer (n = 72) Time on Study (Weeks) NaPi2b Expression Abbreviations: CR = complete response; PR = partial response; H = Higher NaPi2b Expression ; L = Lower NaPi2b

Slide 26: Median Duration of Response Estimated to be ~5 Months in Higher NaPi2b
Median Duration of Response Estimated to be ~5 Months in Patients with Higher NaPi2b Expression 26 Durability of Response in Patients with Ovarian Cancer and Higher NaPi2b (n = 10) Median Duration of Response: ~5 months • 2 patients with Lower NaPi2b with DOR of 16.1 and 17.1 weeks, respectively • 1

Slide 27: Conclusions: UpRi Expansion in Ovarian Cancer
Conclusions: UpRi (XMT - 1536) Expansion in Ovarian Cancer 27 • In this updated analysis of patients with ovarian cancer, UpRi (XMT - 1536) continued to be generally well - tolerated with a consistent profile – no severe neutropenia, peripheral neuropathy, or ocular toxicity • Consistent antitumor a

Slide 28: Ovarian Cancer Market Dynamics and UpRi Opportunities
UpRi (XMT - 1536): First - in - Class Dolaflexin ADC Targeting NaPi2b Ovarian Cancer Market Dynamics and UpRi Opportunities Brian DeSchuytner SVP Finance & Product Strategy

Slide 29: Early Use of Bevacizumab and PARP Inhibitors is Changing the Ovarian Cancer Landscape
29 Frontline Therapy Surgery +/ - Neoadjuvant Platinum - Based Chemotherapy Platinum Sensitive Recurrence Platinum Doublet +/ - Bev +/ - PARP Maintenance +/ - Bev PARP Maintenance Platinum Doublet +/ - Bev +/ - PARP Maintenance PARP (if BRC/HRD 2 – 3 Prior) Platinum Resistant Recurrence PLD, Topotec

Slide 30: Creating New Unmet Needs and Patient Populations
Creating New Unmet Needs and Patient Populations 30 Frontline Therapy Surgery +/ - Neoadjuvant Platinum - Based Chemotherapy Platinum Sensitive Recurrence Platinum Doublet +/ - Bev +/ - PARP Maintenance +/ - Bev PARP Maintenance Platinum Doublet +/ - Bev +/ - PARP Maintenance PARP (if BRCA/HRD 2 - 3

Slide 31: Opportunities to Evaluate UpRi in Practice Changing Clinical Studies
And Opportunities to Evaluate UpRi in Practice Changing Clinical Studies 31 Frontline Therapy Surgery +/ - Neoadjuvant Platinum - Based Chemotherapy Platinum Sensitive Recurrence Platinum Doublet +/ - Bev +/ - PARP Maintenance +/ - Bev PARP Maintenance Platinum Doublet +/ - Bev +/ - PARP Maintenance

Slide 32: UpRi Profile May Offer Potential Advantages in Combination
UpRi Profile May Offer Potential Advantages in Combination 32 0 20 40 60 80 100 Constipation AST Increased Nausea Vomiting Hypomagnesemia Peripheral Neuropathy Anemia Fatigue Thrombocytopenia Neutropenia Grade 3+ All Grades Adverse Events Observed in > 30% of Patients Treated with Lifastuzumab Vedot

Slide 33: UpRi: An Opportunity to Deliver a Potentially Foundational Therapy
33 UpRi (XMT - 1536): An Opportunity to Deliver a Potentially Foundational Therapy for Ovarian Cancer INCREASING MARKET POTENTIAL . Earlier Lines of Therapy New Combinations UPGRADE Umbrella Combo Starting with Platinum Additional Combinations under Consideration Treatment and Maintenance Options un

Slide 34: XMT-1660: First-in-Class B7-H4 ADC
XMT - 1660: First - in - Class B7 - H4 ADC Timothy B. Lowinger, PhD Chief Science & Technology Officer

Slide 35: B7-H4 Expression Well-Suited for a DolaLock ADC
B7 - H4 Expression Well - Suited for a DolaLock ADC • B7 - H4 is selectively expressed on tumor cells in multiple indications – Limited expression in normal tissues • A DolaLock ADC targeting B7 - H4 has the potential to exert its effect through multiple mechanisms of action: – Uptake by tumor cells

Slide 36: B7-H4 Expression Well-Suited for a DolaLock ADC
B7 - H4 Expression Well - Suited for a DolaLock ADC • B7 - H4 is selectively expressed on tumor cells in multiple indications – Limited expression in normal tissues • A DolaLock ADC targeting B7 - H4 has the potential to exert its effect through multiple mechanisms of action: – Uptake by tumor cells

Slide 37: B7-H4 Expression Well-Suited for a DolaLock ADC
B7 - H4 Expression Well - Suited for a DolaLock ADC 37 TUMOR CELL CATABOLIZES ADC Immune Response AF - HPA Diffusion Bystander Effect DENDRITIC CELL ACTIVATION BY AF - HPA BYSTANDER KILLING IMMUNOGENIC CELL DEATH (ICD) ICD B7 - H4 B7 - H4 TUMOR KILLING TUMOR KILLING Tumor Microenvironment • B7 - H4

Slide 38: B7-H4 Expression Well-Suited for a DolaLock ADC
B7 - H4 Expression Well - Suited for a DolaLock ADC 38 TUMOR CELL CATABOLIZES ADC Immune Response AF - HPA Diffusion Bystander Effect DENDRITIC CELL ACTIVATION BY AF - HPA BYSTANDER KILLING IMMUNOGENIC CELL DEATH (ICD) ICD B7 - H4 B7 - H4 TUMOR KILLING TUMOR KILLING T CELL PRIMING Tumor Microenviron

Slide 39: B7-H4 Expression Well-Suited for a DolaLock ADC
B7 - H4 Expression Well - Suited for a DolaLock ADC 39 TUMOR CELL CATABOLIZES ADC Immune Response AF - HPA Diffusion Bystander Effect DENDRITIC CELL ACTIVATION BY AF - HPA BYSTANDER KILLING IMMUNOGENIC CELL DEATH (ICD) ICD B7 - H4 B7 - H4 B7 - H4 B7 - H4 TUMOR KILLING TUMOR KILLING TUMOR - ASSOCIATE

Slide 40: B7-H4 Expression Well-Suited for a DolaLock ADC: The Perfect Storm
B7 - H4 Expression Well - Suited for a DolaLock ADC 40 TUMOR CELL CATABOLIZES ADC Immune Response AF - HPA Diffusion Bystander Effect DENDRITIC CELL ACTIVATION BY AF - HPA BYSTANDER KILLING IMMUNOGENIC CELL DEATH (ICD) ICD B7 - H4 B7 - H4 B7 - H4 B7 - H4 TUMOR KILLING TUMOR KILLING TUMOR - ASSOCIATE

Slide 41: Our DolaLock Payload is Both Cytotoxic and Immunostimulatory
Our DolaLock Payload is Both Cytotoxic and Immunostimulatory Calreticulin surface translocation ATP release 0 5 10 15 20 25 30 35 Concentration ATP nM LPS (positive control) DMSO (negative control) Dolastatin - 10 @ 100 nM AF - HPA @ 100 nM AF - HPA induces immunogenic cell death Dolaflexin ADC AF -

Slide 42: B7-H4 is Expressed in Multiple Cancer Indications with High Unmet Medical Need
B7 - H4 is Expressed in Multiple Cancer Indications with High Unmet Medical Need 42 Protein expression data: • 2 - 3+ IHC B7 - H4 staining/H>50 in >50% of samples in TNBC, uterine, ovarian cancer (Sachdev et al. ASCO, 2019) n= not stated • B7 - H4 Expression (aggregate 1 - 3+ immunoreactivity) in 77

Slide 43: Targeting B7-H4 Creates Opportunities to Address Patients Poorly Served by Checkpoint Inhibitors
Targeting B7 - H4 Creates Opportunities to Potentially Address Patients Poorly Served by Checkpoint Inhibitors PD - L1 and B7 - H4 expression are essentially mutually exclusive • No co - expression in >95% of breast cancer and lung cancer samples* 43 Case 1 Case 2 Breast Cancer Examples PD - L1 B7 -

Slide 44: XMT-1660 Selected Candidate Based on Direct Comparison Across Multiple In Vivo Models
XMT - 1660 Selected Candidate Based on Direct Comparison Across Multiple In Vivo Models, including PDX Models 44 site specific Dolasynthen DAR 2 stochastic Dolaflexin DAR 12 site specific Dolasynthen DAR 6 XMT - 1660 Solid lines indicate equivalent dose by payload; dashed line = 0.5x dose Non - bind

Slide 45: Preclinical Profile of XMT-1660 Supports Advancement
Preclinical Profile of XMT - 1660 Supports Advancement 45 • Pharmacokinetic profile displays long half life (~5 days in NHPs) and dose - dependent exposure – Highly stable with very low (<0.1%) free payload detected in circulation • Well tolerated in NHPs after multiple doses • Demonstrated therapeu

Slide 46: Summary of the Opportunity
Summary of the Opportunity 46 • Potential first - in - class opportunity with compelling target biology and unique fit to DolaLock payload • Clinical candidate was optimized on multiple parameters – DAR, site specific bioconjugation, selection of optimal antibody – Dolasynthen DAR - 6 consistently o

Slide 47: Anna Protopapas, President & CEO
Corporate Update Anna Protopapas President & CEO

Slide 48: >30% ORR with CRs in Ovarian Cancer Patients with Higher NaPi2b Expression
>30% ORR with CRs in Ovarian Cancer Patients with Higher NaPi2b Expression No Severe Neutropenia, Ocular T oxicity , or Peripheral N europathy • Majority of patients pre - treated with PARP inhibitors or bevacizumab; 35% with 4 or more prior lines – Complete response observed in 2 patients with plat

Slide 49: UpRi: An Opportunity to Deliver a Potentially Foundational Therapy
49 UpRi (XMT - 1536): An Opportunity to Deliver a Potentially Foundational Therapy for Ovarian Cancer INCREASING MARKET POTENTIAL . UPLIFT Earlier Lines of Therapy New Combinations Single - Arm Registration Strategy in Platinum Resistant Disease UPGRADE Umbrella Combo Starting with Platinum Addition

Slide 50: Goals and Anticipated Milestones for 2021
Goals and Anticipated Milestones for 2021 50 Upifitamab Rilsodotin UpRi (XMT - 1536) • Q1 2021: Initiate UPLIFT single - arm registration strategy as amendment • Q3 2021: Initiate UPGRADE combination dose escalation umbrella study • 2H 2021: Report updated interim data from NSCLC expansion cohort XM

Slide 51: We are Leveraging our Novel ADC Platforms to Generate Differentiated Product Candidates
51 ADC Program Target Indication Platform Discovery Preclinical P1 Dose Escalation P1 Proof of Concept P2/Pivotal XMT - 1536* NaPi2b Ovarian Cancer Dolaflexin NSCLC Adenocarcinoma Dolaflexin XMT - 1592* NaPi2b Ovarian Cancer NSCLC Adenocarcinoma Dolasynthen XMT - 1660 B7 - H4 Multiple Solid Tumors D

Slide 52: Anticipated Pipeline Progress in 2021
52 ADC Program Target Indication Platform Discovery Preclinical P1 Dose Escalation P1 Proof of Concept P2/Pivotal XMT - 1536* NaPi2b Ovarian Cancer Dolaflexin NSCLC Adenocarcinoma Dolaflexin XMT - 1592* NaPi2b Ovarian Cancer NSCLC Adenocarcinoma Dolasynthen XMT - 1660 B7 - H4 Multiple Solid Tumors D

Slide 53: Question & Answer Session
Question & Answer Session
Source: SEC EDGAR · 8-K filed Jan 5, 2021
More decks from Mersana Therapeutics Inc
Investor Presentation (August 2025)35 slides · Aug 13, 2025
Technical Presentation (January 2025)22 slides · Jan 10, 2025
Technical Presentation (September 2021)32 slides · Sep 10, 2021
Investor Presentation (January 2020)27 slides · Jan 10, 2020
Investor Presentation (February 2019)24 slides · Feb 28, 2019